Patent EP0412554B1 successfully refreshed from Google Patents.
EP0412554B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Sustained-release preparation for administration into brain
Assignee: Koken Co Ltd
•
Filing: 1990-08-10
•
Granted: 1994-11-02
•
Expires: 2010-08-10
Abstract
Abstract Use of a pharmaceutically active substance for the treatment of cerebral diseases by administering into the brain a pharmaceutically active substance for the treatment of cerebral diseases in the form of a sustained-release preparation comprising the pharmaceutically active substance incorporated into a biodegradable carrier.
Inventors
- 👤 Toru Hayakawa
- 👤 Toshiki Yoshimine
- 👤 Keiji Fujioka
- 👤 Yoshihiro Takada
- 👤 Yoshio Sasaki
- 👤 Tsunemasa Irie
- 👤 Nobuyuki Fukushima
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 17:47
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1808; A61K38/1825; A61K38/185; A61K9/00; A61K9/0012; A61K9/0085; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2063; A61K9/70
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
65 words
Use of a brain peptide, a derivative thereof, an antibody, an agonist or an antagonist thereof as an active substance incorporated into a biodegradable carrier selected from the group consisting of collagen, gelatin or a mixture thereof for the preparation of a sustained-release preparation for the treatment of cerebral diseases whereby the treatment achieves diffusion and continuous distribution of the active substance throughout the brain.
Claim 2
Dependent Claim
17 words
The use according to claim 1, wherein said treatment is by administering said preparation into the brain.
Claim 3
Dependent Claim
17 words
The use according to claims 1 or 2, wherein said sustained-release preparation is implanted within the brain.
Claim 4
Dependent Claim
17 words
The use according to claims 1 or 2, wherein said sustained-release preparation is inserted within the brain.
Claim 5
Dependent Claim
23 words
The use according to any one of claims 1 to 4, wherein said active substance is an antibiotic agent or an anticancer agent.
Claim 6
Dependent Claim
32 words
The use according to anyone of claims 1 to 4, wherein said brain peptide is a neurotrophic factor, a cell growth factor, a neurotransmitter-related compound, an immuno-stimulator or a tumor necrosis factor.
Claim 7
Dependent Claim
29 words
The use according to claim 6, wherein said neurotrophic factor is nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), NT-3 or hippocampus-derived neurotrophic factor.
Claim 8
Dependent Claim
14 words
The use according to claim 7, wherein said hippocampus-derived neurotrophic factor is hippocampus factor.
Claim 9
Dependent Claim
28 words
The use according to claim 6, wherein said cell according to claim 7, wherein said cell growth factor is epidermal growth factor (EGF) or fibroblast growth factor (FGF).
Claim 10
Dependent Claim
15 words
The use according to claim 6, wherein said neurotransmitter-related compound is cholecystokinin (CCK) or vasopressin.
Claim 11
Dependent Claim
13 words
The use according to claim 6, wherein said immuno-stimulator is interleukin or interferon.
Claim 12
Dependent Claim
17 words
The use according to any one of claims 1 to 11, wherein said biodegradable carrier is collagen.
Claim 13
Dependent Claim
11 words
The use according to claim 12, wherein said collagen is atelocollagen.
Claim 14
Dependent Claim
20 words
The use according to any one of claims 1 to 13, wherein said sustained-release preparation is a formed solid preparation.
Claim 15
Dependent Claim
32 words
The use according to any one of claims 1-4 and 6-14, wherein said substance for the treatment of cerebral diseases is a substance which is not substantially transferred through the blood-brain barrier.
Claim 16
Dependent Claim
14 words
The use according to claim 6, wherein the neurotrophic factor is nerve growth factor.
Claim 17
Dependent Claim
15 words
The use according to claim 6, wherein the neurotrophic factor is brain derived neurotrophic factor.
Claim 18
Dependent Claim
14 words
The use according to claim 6, wherein the neurotrophic factor is ciliary neurotrophic factor.
Claim 19
Dependent Claim
11 words
The use according to claim 6, wherein the immuno-stimulator is interferon.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.